Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.56 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | ENTPD1 | P49961 | 1/20 | 0.52 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2317501 | 0.94 | FBP1 (0.54) | FBP1 | |
| SCHEMBL8388000 | 0.92 | FBP1 (0.64) | FBP1SIRT2SIRT1ENTPD1 | |
| SCHEMBL20266254 | 0.91 | FBP1 (0.63) | FBP1SIRT2SIRT1ENTPD1 | |
| Adenosine Phosphate SCHEMBL31666008 | 0.88 | P2RY1 (0.69) | FBP1RNASEL | |
| Adenosine Phosphate SCHEMBL20529828 | 0.85 | P2RY1 (0.65) | FBP1RNASEL | |
| SCHEMBL4209829 | 0.85 | ENTPD1 (0.66) | FBP1ENTPD1 | |
| SCHEMBL10686147 | 0.85 | FBP1 (0.68) | FBP1SIRT2SIRT1ENTPD1 | |
| SCHEMBL4206199 | 0.84 | ENTPD1 (0.67) | FBP1ENTPD1 | |
| Lithium Ion SCHEMBL20266257 | 0.84 | FBP1 (0.60) | FBP1SIRT2SIRT1ENTPD1 | |
| Lithium Ion SCHEMBL30999928 | 0.84 | FBP1 (0.60) | FBP1SIRT2SIRT1ENTPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110189664-A1 | DIAGNOSTICS IN A MONOPLEX/MULTIPLEX FORMAT | UNIVERSITY OF WOLLONGONG | 2011-08-04 | — | — | US | disclosed |
| US-20090286696-A1 | Double-Stranded Olidonucleotides and Uses Therefor | UNIVERSITY OF WOLLONGONG | 2009-11-19 | — | — | US | disclosed |
| WO-2008148143-A1 | DIAGNOSTICS IN A MONOPLEX/MULTIPLEX FORMAT | UNIVERSITY OF WOLLONGONG (AU) | 2008-12-11 | — | — | WO | disclosed |
| WO-2006081623-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDES AND USES THEREFOR | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286696-A1 | Double-Stranded Olidonucleotides and Uses Therefor | DNTT, ADAR, DUT | FBP1 3887/4885SIRT2 3550/4885SIRT1 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.